| 24.1101 -0.96 (-3.83%) | 01-30 10:10 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 31.09 | 1-year : | 36.32 |
| Resists | First : | 26.62 | Second : | 31.09 |
| Pivot price | 23.62  |
|||
| Supports | First : | 22 | Second : | 19.14 |
| MAs | MA(5) : | 25.23  |
MA(20) : | 22.75 |
| MA(100) : | 17.38 |
MA(250) : | 12.37 |
|
| MACD | MACD : | 1.3 |
Signal : | 1.2 |
| %K %D | K(14,3) : | 77.6 |
D(3) : | 80 |
| RSI | RSI(14): 64.1 |
|||
| 52-week | High : | 26.62 | Low : | 5.15 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IMNM ] has closed below upper band by 30.7%. Bollinger Bands are 93.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 25.63 - 25.76 | 25.76 - 25.87 |
| Low: | 23.99 - 24.13 | 24.13 - 24.25 |
| Close: | 24.86 - 25.08 | 25.08 - 25.27 |
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Sat, 24 Jan 2026
Institutional Investors Are Immunome, Inc.'s (NASDAQ:IMNM) Biggest Bettors and Were Rewarded After Last Week's US$382m Market Cap Gain - 富途牛牛
Sun, 18 Jan 2026
Immunome (IMNM) Is Up 6.4% After Strong Phase 3 Varegacestat Data and 2026 FDA Plan - What's Changed - simplywall.st
Sat, 17 Jan 2026
Immunome (IMNM) Is Up 6.4% After Strong Phase 3 Varegacestat Data and 2026 FDA Plan - What's Changed - Sahm
Fri, 16 Jan 2026
Immunome (IMNM) Is Up 11.7% After Phase 3 Varegacestat Success - Has The Bull Case Changed? - Yahoo Finance
Thu, 15 Jan 2026
Assessing Immunome (IMNM) Valuation After Phase 3 Success And Upcoming J.P. Morgan Conference Presentation - Sahm
Thu, 15 Jan 2026
Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now? - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 110 (M) |
| Held by Insiders | 8.662e+007 (%) |
| Held by Institutions | 7.8 (%) |
| Shares Short | 15,270 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.0456e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 137.1 % |
| Return on Equity (ttm) | -46.5 % |
| Qtrly Rev. Growth | 9.68e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -41.73 |
| EBITDA (p.s.) | -7.387e+007 |
| Qtrly Earnings Growth | -3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -185 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.61 |
| Price to Cash Flow | 19.52 |
| Dividend | 0 |
| Forward Dividend | 1.753e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|